Evidence map›Paper›PMID 28750897›Full record

ArticleInternational journal of pharmaceutics2017

Inhibition of Clostridium perfringens epsilon toxin by β-cyclodextrin derivatives.

Tanisha M Robinson, Laszlo Jicsinszky, Andrei V Karginov, Vladimir A Karginov

Abstract read
In one paragraph

Article in International journal of pharmaceutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Mechanochemical Degradation of Biopolymers.Molecules (Basel, Switzerland) · 2023
    Review
  2. Review
  3. Cyclodextrins in the antiviral therapy.Journal of drug delivery science and technology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Tanisha M RobinsonInnovative Biologics, Inc., Herndon, VA, USA.
Laszlo JicsinszkyInnovative Biologics, Inc., Herndon, VA, USA; Dipartimento di Scienza e Tecnologia del Farmaco, University of Turin, Turin, Italy.
Andrei V KarginovDepartment of Pharmacology, University of Illinois at Chicago, Illinois, USA.
Vladimir A KarginovInnovative Biologics, Inc., Herndon, VA, USA. Electronic address: vak@kfbllc.com.
Innovative Biologics (United States) · USUniversity of Illinois Chicago · US

Funding

TRPC6 Regulation of Lung Endothelial Barrier FunctionP01HL060678 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI MALIK, ASRAR B. · 2000 to 2020
$40.1M
Small Molecule Inhibitors of C. perfringens Epsilon-ToxinR44AI074105 · NIAID · INNOVATIVE BIOLOGICS, INC · PI KARGINOV, VLADIMIR A · 2008 to 2009
$741k
Small Molecule Inhibitors of C. perfringens Epsilon-ToxinR43AI074105 · NIAID · INNOVATIVE BIOLOGICS, INC · PI KARGINOV, VLADIMIR A · 2007 to 2007
$99k
NHLBI NIH HHS P01 HL060678NIAID NIH HHS R43 AI074105NIAID NIH HHS R44 AI074105
6 · The paper itself

Abstract

Clostridium perfringens epsilon toxin (ETX) is considered as one of the most dangerous potential biological weapons. The goal of this work was to identify inhibitors of ETX using a novel approach for the inactivation of pore-forming toxins. The approach is based on the blocking of the target pore with molecules having the same symmetry as the pore itself. About 200 various β-cyclodextrin derivatives were screened for inhibitors of ETX activity using a colorimetric cell viability assay. Several compounds with dose-dependent activities at low micromolar concentrations have been identified. The same compounds were also able to inhibit lethal toxin of Bacillus anthracis.

Indexed as

Bacillus anthracisBacterial Toxinsbeta-CyclodextrinsClostridium perfringensBacterial Toxinsbeta-CyclodextrinsBacillus anthracisClostridium perfringensLethal toxinToxin inhibitorsβ-cyclodextrin derivativesε-toxin

Identifiers

PMID28750897
PMCPMC5623079
OpenAlexW2738301759

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.